Abbvie Inc
Abbvie Inc (ABBV) Option Chain
Abbvie Inc trades at $295.03, up 0.20%, with an IV Rank of 23.61%. This is low versus the past year, and the company carries a market cap of $521,500M in the Drug Manufacturers - General industry. On the Nov 20, 2026 chain, the at the money $295.00 strike shows calls at $3.90 / $4.65 and puts at $3.70 / $5.00, both carrying about $4.30 of extrinsic value and a roughly 50% probability of expiring out of the money. Volume is heaviest on the $297.50 calls, at 217 contracts, and the $290.00 puts, at 859, as of Nov 13, 2026.
Read more
Tracking the ABBV option chain helps you see every strike and expiry on Abbvie Inc in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of ABBV options activity at a glance. Use our scanner to monitor the ABBV option chain in real time and filter for the trades that actually meet your criteria.
An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For ABBV stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where ABBV options are being actively traded, and where they are not.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
| CALLs | PUTs | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prob. OTM % | Open Interest | Volume | Extrinsic Value | Intrinsic Value | Bid | Ask | Strike | Moneyness % | Bid | Ask | Intrinsic Value | Extrinsic Value | Volume | Open Interest | Prob. OTM % |
| 31.16 | 8,790 | 152 | 2.42 | 5.03 | 6.85 | 8.05 | 290.00 | -1.70 | 1.99 | 2.37 | 0.00 | 2.18 | 859 | 571 | 68.84 |
| 40.20 | 357 | 15 | 3.40 | 2.53 | 5.60 | 6.25 | 292.50 | -0.86 | 2.73 | 3.45 | 0.00 | 3.09 | 17 | 37 | 59.80 |
| 49.73 | 278 | 163 | 4.25 | 0.03 | 3.90 | 4.65 | 295.00 | -0.01 | 3.70 | 5.00 | 0.00 | 4.35 | 31 | 260 | 50.27 |
| 59.18 | 225 | 217 | 3.17 | 0.00 | 2.78 | 3.55 | 297.50 | +0.84 | 4.00 | 6.70 | 2.47 | 2.88 | 17 | 86 | 40.82 |
| 68.06 | 3,142 | 61 | 2.19 | 0.00 | 1.92 | 2.46 | 300.00 | +1.68 | 6.00 | 7.45 | 4.97 | 1.75 | 9 | 52 | 31.94 |
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryDrug Manufacturers - General
- SectorHealthcare
- IV Rank23.61% Low
- Market cap (M$)521,500
- 52 weeks high-2.61%
- 52 weeks low54.67%
- Analyst recommendationBuy
1.57 - Target price$314.81
6.70% above the current stock price - Dividend—
- Payout ratio281.66%
- Earnings date2027-02-03
- P/E50.78
- Future P/E18.14
- EPS (ttm)5.81
- EPS growth next 5 years21.77%
As of Nov 13, 2026